Cat. No.: HY-16294

LY2090314

22 Cited Publications

Avis client

Based on 22 publication(s) in Google Scholar

LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC₅₀ values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.85%
CAS No.: 603288-22-8
Formule: C₂₈H₂₅FN₆O₃
Masse moléculaire:512.53

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

LY2090314 Chemical Structure

CAS No.: 603288-22-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (22)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC₅₀ values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.

IC₅₀ & Target^[1]

GSK-3β

0.9 nM (IC₅₀)

GSK-3α

1.5 nM (IC₅₀)

Voir tous les produits spécifiques à Isoform GSK-3 :

Cellular Effect

Cell Line	Type	Value	Description	References
A2058	IC₅₀	0.008 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human A2058 cells harboring BRAF V600E/PTEN null mutation assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human A2058 cells harboring BRAF V600E/PTEN null mutation assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
A-375	IC₅₀	0.008 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human vemurafenib-resistant A-375 cells harboring BRAF V600E mutation assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human vemurafenib-resistant A-375 cells harboring BRAF V600E mutation assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
A-375	IC₅₀	0.01 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human A-375 cells harboring BRAF V600E mutation assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human A-375 cells harboring BRAF V600E mutation assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
A549	IC₅₀	9.96 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human A549 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human A549 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
BXPC-3	IC₅₀	0.43 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human BXPC-3 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human BXPC-3 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
CHL-1	IC₅₀	0.11 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human CHL-1 cells assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human CHL-1 cells assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
COLO 205	IC₅₀	11.3 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human COLO 205 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human COLO 205 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
COLO 320	IC₅₀	>20 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human COLO 320 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human COLO 320 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
DU-145	IC₅₀	5.52 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human DU-145 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human DU-145 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
HCT-116	IC₅₀	10.48 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human HCT-116 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human HCT-116 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
LNCaP	IC₅₀	0.15 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human LNCaP assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human LNCaP assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
M14	IC₅₀	0.007 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human M14 cells harboring BRAF V600E mutation assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human M14 cells harboring BRAF V600E mutation assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
M14	IC₅₀	0.007 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human vemurafenib-resistant M14 cells harboring BRAF V600E mutation assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human vemurafenib-resistant M14 cells harboring BRAF V600E mutation assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
MCF7	IC₅₀	>20 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human MCF7 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human MCF7 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
MDA-MB-231	IC₅₀	>20 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human MDA-MB-231 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human MDA-MB-231 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
MDA-MB-468	IC₅₀	0.45 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
NCI-H2030	IC₅₀	9.44 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human H2030 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human H2030 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
NCI-H460	IC₅₀	13.25 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human H460 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human H460 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
RKO	IC₅₀	>20 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human RKO assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human RKO assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
SK-BR-3	IC₅₀	>20 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human SK-BR-3 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human SK-BR-3 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
SK-MEL-2	IC₅₀	0.006 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human SK-MEL-2 cells harboring NRAS Q61R mutation assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human SK-MEL-2 cells harboring NRAS Q61R mutation assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
SK-MEL-28	IC₅₀	>10 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human SK-MEL-28 cells harboring BRAF V600E mutation assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human SK-MEL-28 cells harboring BRAF V600E mutation assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]
SK-MES-1	IC₅₀	>20 μM Compound: Chemical probe : LY2090314	Antiproliferative activity against human SK-MES-1 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay Antiproliferative activity against human SK-MES-1 assessed as reduction in cell viability incubated for 72 hrs by CellTitre-Glo assay	[PMID: 25915038]

In Vitro

LY2090314 (20 nM) promotes a time-dependent stabilization of β-catenin total protein as well as an induction of Axin2. LY2090314 is highly selective towards GSK3 as demonstrated by its fold selectivity relative to a large panel of kinases. LY2090314 potently induces apoptotic cell death in a panel of melanoma cell lines irrespective of BRAF mutation status. Cell death induced by LY2090314 is dependent on β-catenin and GSK3β knockdown increases the sensitivity of cells to LY2090314. LY2090314 remains active in cell lines resistant to PLX4032 and has an independent mechanism of action^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

LY2090314 exhibits high clearance (approximating hepatic blood flow) and a moderate volume of distribution (appr 1-2 L/kg) resulting in rapid elimination (half-life appr 0.4, 0.7, and 1.8-3.4 hours in rats, dogs, and humans, respectively). LY2090314 is rapidly cleared by extensive metabolism with negligible circulating metabolite exposures due to biliary excretion of metabolites into feces with no apparent intestinal reabsorption^[1].
LY2090314 (25 mg/kg Q3D, i.v.) elevates Axin2 gene expression in vivo, demonstrates single agent activity in the A375 xenograft model of melanoma and enhances the efficacy of DTIC^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 603288-22-8
Appearance Solid
Masse moléculaire 512.53
Formule C₂₈H₂₅FN₆O₃
Color Orange to reddish brown
SMILES

O=C(C(C1=CN2CCN(C(N3CCCCC3)=O)CC4=CC(F)=CC1=C42)=C5C6=CN=C7C=CC=CN76)NC5=O
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (22)

All WBIHC

Sort by:

Journal Impact Factor

Nature

Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation. [Abstract]

2025 Jun;642(8067):508-518. PMID: 40240608
Mol Cancer

ROCK1 inhibition primes anti-tumor immunity in EGFR-mutant NSCLC by triggering PD-L1 degradation mediated by SMURF2. [Abstract]

2026 Apr 2;25(1):130. PMID: 41928228
Cell Res

Modeling post-gastrula development via bidirectional pluripotent stem cells. [Abstract]

2025 Aug 29. PMID: 40883608
Cell Res

Derivation of totipotent-like stem cells with blastocyst-like structure forming potential. [Abstract]

2022 Jun;32(6):513-529. PMID: 35508506
Nat Commun

Human PI3Kγ deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue immunopathology. [Abstract]

2019 Sep 25;10(1):4364. PMID: 31554793
J Biomed Sci

SARS-CoV-2 membrane protein recruits PP2A to dephosphorylate the nucleocapsid and promote virion production. [Abstract]

2026 May 15;33(1):51. PMID: 42141450
Cell Rep

Biphasic control of the B cell transcriptome by mTORC1 and GSK3. [Abstract]

2025 Sep 29;44(10):116361. PMID: 41026602
Sci Data

High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]

2024 Sep 19;11(1):1024. PMID: 39300112
Int J Mol Sci

Toward Xeno-Free Differentiation of Human Induced Pluripotent Stem Cell-Derived Small Intestinal Epithelial Cells. [Abstract]

2022 Jan 24;23(3):1312. PMID: 35163236
Int Immunopharmacol

Berberine coated mannosylated liposomes curtail RANKL stimulated osteoclastogenesis through the modulation of GSK3β pathway via upregulating miR-23a. [Abstract]

2019 Sep:74:105703. PMID: 31261037
Stem Cell Reports

Efficient Generation of Small Intestinal Epithelial-like Cells from Human iPSCs for Drug Absorption and Metabolism Studies. [Abstract]

2018 Dec 11;11(6):1539-1550. PMID: 30472010

LY2090314 purchased from MedChemExpress. Usage Cited in: Stem Cell Reports. 2018 Dec 11;11(6):1539-1550. [Abstract]

The CDX2 protein expression levels are measured by western blotting analysis in the treatment of SB216763, CHIR99021, LY2090314, BIO and BIO.DAPT.

LY2090314 purchased from MedChemExpress. Usage Cited in: Stem Cell Reports. 2018 Dec 11;11(6):1539-1550. [Abstract]

Immunostaining analysis of CDX2 (green) is performed in the human iPSC-derived intestinal progenitor cells in the treatment of LY2090314.
Mol Ther Methods Clin Dev

Vinblastine treatment decreases the undifferentiated cell contamination of human iPSC-derived intestinal epithelial-like cells. [Abstract]

2021 Jan 20:20:463-472. PMID: 33614822
Mol Ther Methods Clin Dev

Establishment of SLC15A1/PEPT1-Knockout Human-Induced Pluripotent Stem Cell Line for Intestinal Drug Absorption Studies. [Abstract]

2019 Nov 21:17:49-57. PMID: 31890740
FASEB J

Deletion of the tyrosine phosphatase Shp2 in cervical cancer cells promotes reprogramming of glutamine metabolism. [Abstract]

2023 Apr;37(4):e22880. PMID: 36943407
J Biol Chem

Her4.3+ radial glial cells maintain the brain vascular network through activation of Wnt signaling. [Abstract]

2024 Aug;300(8):107570. PMID: 39019216
J Biol Chem

Glycogen Synthase Kinase 3 (GSK-3)-mediated Phosphorylation of Uracil N-Glycosylase 2 (UNG2) Facilitates the Repair of Floxuridine-induced DNA Lesions and Promotes Cell Survival. [Abstract]

2016 Dec 23;291(52):26875-26885. PMID: 27875297

LY2090314 purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2016 Dec 23;291(52):26875-26885. [Abstract]

K562 cells expressing wild-type S-UNG2 are treated with the GSK-3 inhibitor LY2090314 (LY) for 90 min. Phosphorylation of UNG2 is detected with phospho-PLK1 motif antibody (top). UNG2 expression in input cell lysates is detected by Western blotting for the S tag (bottom).
SLAS Discov

Development of a live cell assay for real-time monitoring the interactions between the Hippo pathway components 14-3-3 and TAZ. [Abstract]

2024 Nov 5;29(8):100191. PMID: 39510350
bioRxiv

2025 Oct 6.
SSRN

2025 Jul 25.
SSRN

2025 Feb 24.
Patent

US20230190767A1.
Elife

Cohesin mutations are synthetic lethal with stimulation of WNT signaling. [Abstract]

2020 Dec 7:9:e61405. PMID: 33284104

Solvant et solubilité

In Vitro:

DMSO : 25 mg/mL (48.78 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9511 mL

9.7555 mL

19.5111 mL

5 mM

0.3902 mL

1.9511 mL

3.9022 mL

10 mM

0.1951 mL

0.9756 mL

1.9511 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.25 mg/mL (2.44 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.25 mg/mL (2.44 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 20% HP-β-CD/10 mM Citrate pH 2.0

Solubility: 10 mg/mL (19.51 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Animal Administration^[2]

Five million A375 human melanoma cancer cells are injected S.C. in the flank of female 6 to 8 week old athymic nude mice in a 1:1 mixture with matrigel. Mice are monitored daily for palpable tumors. When tumors reach appr 100 mm² mice are randomized into groups receiving either LY2090314 (25 mg/kg Q3D) or vehicle (20% Captisol/0.01N HCl) via i.v. administration. Tumor volume (measured by calipers) and animal body weight are recorded twice weekly. Tumor volumes are calculated using the formula: (a² × b)/2 (a being the smaller and b being the larger dimension of the tumor). For combination studies with DTIC (60 mg/kg QD), LY2090314 is dosed at 2.5 mg/kg Q3D and tumor growth monitored.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (287 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Zamek-Gliszczynski MJ, et al. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure. Dr [Content Brief]

[2]. Atkinson JM, et al. Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3. PLoS One. 2015 Apr 27;10(4):e0125028. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9511 mL	9.7555 mL	19.5111 mL	48.7776 mL
	5 mM	0.3902 mL	1.9511 mL	3.9022 mL	9.7555 mL
	10 mM	0.1951 mL	0.9756 mL	1.9511 mL	4.8778 mL
	15 mM	0.1301 mL	0.6504 mL	1.3007 mL	3.2518 mL
	20 mM	0.0976 mL	0.4878 mL	0.9756 mL	2.4389 mL
	25 mM	0.0780 mL	0.3902 mL	0.7804 mL	1.9511 mL
	30 mM	0.0650 mL	0.3252 mL	0.6504 mL	1.6259 mL
	40 mM	0.0488 mL	0.2439 mL	0.4878 mL	1.2194 mL

Keywords

LY2090314

22 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

LY2090314

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Targeted Diversity Library

Antidepressant Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Anti-Aging Compound Library Mini

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) LY2090314

Voir tous les produits spécifiques à Isoform GSK-3

Activité biologique

Chemical Information

Publications (22)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

LY2090314 Related Classifications

HY-16294 Related Classifications